ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
May 04 2015 - 11:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that the following
presentations by Company management at upcoming investor
conferences will be webcast:
- Credit Suisse Antibody Day
2015
- Jefferies 2015 Global Healthcare
Conference
Scheduling information and the webcasts will be accessible
through the “Investors” section of the Company’s website,
www.immunogen.com. Webcast replay will be available at the same
location for approximately a week following the conference
presentation date.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells. The
Company utilizes its ADC technology with its antibodies to create
ImmunoGen product candidates and also out-licenses limited rights
to use its technology to other companies. Roche’s Kadcyla® is the
first marketed product with ImmunoGen’s ADC technology. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024